AJMCtv Panel Discussions provide a group of national experts to discuss topics relevant to managed care in a roundtable teleconference format. Our mission is to generate discussion and perspectives among thought-leaders on current issues, which will be of great educational benefit to our managed care audience.
Panel Discussions
In a discussion moderated by AJMC Co-Editor-in-Chief, Michael E. Chernew, PhD, Drs. Lee N. Newcomer, UnitedHealthcare, and Sandra M. Swain, Washington Cancer Institute, Medstar Washington Hospital Center, address the use of combination therapy in the treatment for HER2 positive metastatic breast cancer.
This panel discussion will look into new agents under review for the treatment of melanoma. Drugs currently approved by the US Food and Drug Administration for treatment of melanoma include aldesleukin, dabrafenib, dacarbazine, ipilimumab, trametinib, and vemurafenib. Today, we will examine the use and cost implications of new treatment therapies in development.
This expert panel discussion, moderated by co-editor-in-chief of The American Journal of Managed Care, Dr Mark Fendrick, examined agents used in the treatment of prostate cancer including new immunotherapy agents. Panelists also discussed the role of personalized medicine in prostate cancer. Panelists include Drs David Crawford, Head, Section of Urologic Oncology Professor of Urologic and Radiation Oncology, University of Colorado at Denver University of Colorado Hospital, Daniel George, Director, Prostate Clinic, Genitourinary Oncology, Duke Cancer Institute, and Neal D. Shore, Medical Director of the Carolina Urologic Research Center, Myrtle Beach, South Carolina.
Jan Berger MD, MJ, president & CEO, Health Intelligence Partners, editor-in-chief, The American Journal of Pharmacy Benefits, served as the moderator for this expert panel discussion on genetic testing in oncology. The panelists included, Otis Brawley, MD, chief medical officer, American Cancer Society, David H. Finley, MD, FACS, national medical officer, Enterprise Affordability and Policy, Cigna Healthcare, Joy Larsen-Haidle, MS, genetic counselor, Hubert H. Humphrey Cancer Center, Ellen T. Matloff, MS, research scientist, Department of Genetics, director, Cancer Genetic Counseling, Yale Cancer Center and Rebecca Nagy, MS, genetic counselor, president, National Society of Genetic Counselors.
A panel of health leaders examine treatment strategies, including the new and emerging agents, used to manage patients with non-small cell lung cancer (NSCLC). This discussion includes an overview of NSCLC treatments, molecular target therapies including next generation agents, and the future trends that will influence NSCLC management. Moderated by Michael Chernew, PhD, Harvard University, and co-editor-in-chief of The American Journal of Managed Care, the panel includes Corey J. Langer MD, FACP, Professor of Medicine, Abramson Cancer Center, University of Pennsylvania, David J. Sugarbaker, MD, Chief, Division of Thoracic Surgery, Brigham and Women's Hospital, and, Dr. Steven R. Peskin, MD, Senior Medical Director/Pilot Lead at Horizon Healthcare Innovations, Horizon BCBSNJ.
In an expert panel discussion, moderated by Mark Fendrick MD, co-editor-in-chief of The AJMC, panelists analyze the implications of the US Preventive Services Task Force recommendations on screening baby boomers for the Hepatitis C virus (HCV). The panel members, who included Dr Nezam H. Afdhal, associate professor of medicine, Harvard School of Medicine and chief of hepatology director of liver center, Beth Israel Deaconess Medical Center, Dr Steven Miller, senior vice President and chief medical officer at Express Scripts, and Dr David Winston, director, gastroenterology and hepatology, CIGNA, discuss the current and new therapies for HCV, along with the clinical and economic outcome of the Affordable Care Act mandate for coverage of USPSTF recommendations by health plans.